Clinical Trials Logo

Lipoprotein Lipase Deficiency clinical trials

View clinical trials related to Lipoprotein Lipase Deficiency.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03360747 Completed - Clinical trials for Familial Chylomicronemia Syndrome

Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)

Start date: December 21, 2017
Phase: Phase 2
Study type: Interventional

This is a single center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of triglyceride (TG) levels in participants with FCS.

NCT ID: NCT03293810 Completed - Clinical trials for Lipoprotein Lipase Deficiency

Glybera Registry, Lipoprotein Lipase Deficient (LPLD) Patients

GENIALL
Start date: June 27, 2014
Phase:
Study type: Observational [Patient Registry]

Lipoprotein lipase deficiency (LPLD) is a rare autosomal recessive disorder, characterized by loss-of function mutations in the LPL gene, leading to the inability to produce functionally active lipoprotein lipase (LPL). LPL is the key enzyme in the metabolism of triglyceride (TG)-rich lipoproteins (chylomicrons (CM) and very low-density lipoproteins (VLDL)). LPLD results in extremely high concentrations of circulating TG-rich lipoproteins. No drug therapy for LPLD is currently available. Clinical management of LPLD patients consists of severe dietary fat restriction and the use of medium-chain triglycerides to substitute for normal dietary fats. Alipogene tiparvovec (Glybera®) received marketing authorisation from the European commission on 25 October 2012. Glybera® aims to correct lipoprotein lipase deficiency sufficiently to decrease the morbidity and lower the risk of inherent complications of LPLD, in adult patients genetically diagnosed with LPLD. The Glybera Registry is designed to collect the long-term safety and efficacy data of GLYBERA®

NCT ID: NCT02658175 Completed - Clinical trials for Familial Chylomicronemia Syndrome

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome

Start date: December 23, 2015
Phase: Phase 3
Study type: Interventional

An open-label study of volanesorsen (ISIS 304801) administered subcutaneously to participants with FCS.

NCT ID: NCT02656095 Completed - Clinical trials for Lipoprotein Lipase Deficiency

Lipoprotein Lipase Enzyme Activity Assay Validation and Clinical Assessment

Start date: March 2016
Phase:
Study type: Observational

This study plans to learn more about measuring Lipoprotein lipase (LPL) activity in humans. LPL is an enzyme in the breakdown of certain types of fats into smaller parts. Lipoprotein lipase deficiency (LPLD) is a very rare genetic disorder in which lipoprotein enzyme is no longer functional. This can cause conditions known as high triglycerides in the blood and inflammation of the pancreas. Investigational medications to treat LPLD are currently being developed. In order to see if these medications are effective, it is necessary to be able to accurately measure LPL activity in humans. LPL activity has been successfully measured in animal models after giving heparin. Heparin is a blood thinner which is approved by the FDA. It is originally used to prevent blood clots. This study will administer heparin to healthy adults through intravenous infusion (IV). Blood samples will be collected before and after the infusion to test LDL levels. The purpose of this study is to develop a cheap, more reliable standard for assessment of LPLD in patients